Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 366 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Transplant Patients Clear all
Terminated Phase 4 Interventional Results available

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

NCT00658333
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 5, 2026, 5:23 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients

NCT02165761
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GORE® Hybrid Vascular Graft, Non-heparin bonded synthetic graft
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Hackensack, New Jersey • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 5, 2026, 5:23 PM EDT
Completed No phase listed Observational

Natural History Study of Azathioprine Adherence

NCT00143910
View directory record Official record
Conditions
Kidney Transplant
Interventions
observation
Other
Lead sponsor
Thomas E. Nivens, MD
Individual
Eligibility
16 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 5, 2026, 5:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation

NCT07287800
View directory record Official record
Conditions
Hypogonadism, Male, End Stage Renal Disease (ESRD), Kidney Transplant
Interventions
Testosterone Replacement Therapy
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 5, 2026, 5:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

NCT05092347
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Vonsetamig
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

NCT00002673
View directory record Official record
Conditions
Cancer
Interventions
infection prophylaxis and management
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 5, 2026, 5:23 PM EDT
Terminated No phase listed Observational

Kidney Transplantation in Patients With Sickle Cell Disease

NCT00663507
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

NCT00483756
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
37
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 5, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929
View directory record Official record
Conditions
Cancer
Interventions
anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 5, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

NCT00628264
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury
Interventions
AP214, Placebo
Drug
Lead sponsor
Action Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Oct 5, 2026, 5:23 PM EDT
Terminated Early Phase 1 Interventional

Immunosuppressant Medication Dosed Daily After Kidney Transplant

NCT04156204
View directory record Official record
Conditions
Kidney Transplant Rejection, Medication Adherence
Interventions
Medication Event Monitoring System (MEMS), Once-Daily Tacrolimus extended release
Other · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 22 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Improving Medication Safety and CVD Risk Factor Control in Kidney Transplant Recipients

NCT02763943
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Mellitus, Medication Adherence
Interventions
Pharmacist-led, technology enabled education intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 5, 2026, 5:23 PM EDT
Not listed Phase 1 Interventional

B-Cell Targeted Carfilzomib Desensitization

NCT02442648
View directory record Official record
Conditions
Transplants and Implants
Interventions
Carfilzomib, Rituximab
Drug
Lead sponsor
E. Steve Woodle
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Predictors and Intervention for Noncompliance

NCT00148174
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Intensive telephone followup
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
14 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients

NCT03765203
View directory record Official record
Conditions
Transplant;Failure,Kidney
Interventions
Natera KidneyScan, Clinical Performance and Value Vignettes
Diagnostic Test · Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

NCT02981706
View directory record Official record
Conditions
Chronic Kidney Disease, Endstage Renal Disease
Interventions
Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG)
Procedure
Lead sponsor
Columbia University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 5, 2026, 5:23 PM EDT
Not listed Not applicable Interventional

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

NCT00295997
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 74 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
San Francisco, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BK With VST for Kidney Transplant Patients

NCT05042076
View directory record Official record
Conditions
Kidney Transplant Infection, BK Virus Infection
Interventions
BK-specific T cells from Donor Lymphocytes
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CMX001 in Post-transplant Patients With BK Virus Viruria

NCT00793598
View directory record Official record
Conditions
Viruria
Interventions
Placebo, Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

NCT00078559
View directory record Official record
Conditions
Kidney Transplantation, Kidney Disease
Interventions
Alemtuzumab, Sirolimus, Tacrolimus, Kidney transplant, Methylprednisolone (or equivalent), Acetaminophen, Diphenhydramine, Trimethoprim (TMP)/Sulfa (Bactrim, Septra), Valgancyclovir, Acyclovir, Pentamidine, Clotrimazole, Nystatin
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 5, 2026, 5:23 PM EDT
Terminated Phase 4 Interventional

Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias

NCT01623583
View directory record Official record
Conditions
Needle Phobia, Phobic Disorders
Interventions
Enhanced Needle Phobia Intervention, Standard Needle Phobia Intervention
Other
Lead sponsor
Davita Clinical Research
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Rancho Cordova, California • Sacramento, California • Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 5, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

NCT00243009
View directory record Official record
Conditions
Kidney Cancer
Interventions
cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 5, 2026, 5:23 PM EDT
Completed Not applicable Interventional

NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients

NCT01771705
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Dose adjust group (NFAT)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 5, 2026, 5:23 PM EDT
Terminated Phase 2Phase 3 Interventional

The Boston Scientific ACCESS Trial

NCT00260728
View directory record Official record
Conditions
Renal Disease, Kidney Failure
Interventions
vascular access graft implantation
Device
Lead sponsor
Maquet Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Long Beach, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 5, 2026, 5:23 PM EDT